Pharmacokinetics of Co-administration of Seretide 250 Diskus (HCP0910) and Spiriva Capsule for Inhalation (HGP1011)
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This pilot study was designed to evaluate the pharmacokinetic characteristics of fluticasone,
salmeterol, and tiotropium after co-administration of HCP 0910 (Seretide 250 diskus) and
HGP1011 (Spiriva capsule for inhalation) which are prescribed concomitantly for the patients
with chronic obstructive pulmonary disease (COPD).
Phase:
Phase 1
Details
Lead Sponsor:
Seoul National University Hospital
Treatments:
Fluticasone Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Fluticasone-Salmeterol Drug Combination Salmeterol Xinafoate Tiotropium Bromide